Incyte (INCY) Equity Average (2011 - 2026)
Incyte posted quarterly Equity Average of $5.4 billion for Q1 2026, up 51.65% year-on-year from $3.6 billion in Q1 2025, and up 9.9% on a QoQ basis from $4.9 billion in Q4 2025.
Incyte (INCY) has 16 years of Equity Average data on file, last reported at $5.4 billion in Q1 2026.
- For the quarter ending Q1 2026, Equity Average rose 51.65% year-over-year to $5.4 billion; the trailing twelve-month figure through Mar 2026 stood at $5.4 billion (up 51.65% YoY), and the FY2025 full-year result was $4.3 billion, changed 0.26% from the prior year.
- Equity Average for Q1 2026 stood at $5.4 billion, up from $4.9 billion in the prior quarter.
- Across five years, Equity Average topped out at $5.4 billion in Q1 2026 and bottomed at $3.1 billion in Q3 2024.
- The 5-year median for Equity Average is $4.3 billion (2022), against an average of $4.3 billion.
- The widest annual swing landed in 2024, when Equity Average slumped 36.23%; it then soared 51.65% in 2026.
- A 5-year view of Equity Average shows it stood at $4.3 billion in 2022, then rose by 17.73% to $5.1 billion in 2023, then slumped by 34.6% to $3.3 billion in 2024, then soared by 48.34% to $4.9 billion in 2025, then grew by 9.9% to $5.4 billion in 2026.
- The last three Equity Average figures came in at $5.4 billion (Q1 2026), $4.9 billion (Q4 2025), and $4.4 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 3.76 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 21.35 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 19.01 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 31.34 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 932.28 Mn |
| 10 | Incyte | 19.28 Bn | 15.27 Bn | 1.17 Bn | 5.40 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.40 Bn |
| Dec 31, 2025 | 4.91 Bn |
| Sep 30, 2025 | 4.41 Bn |
| Jun 30, 2025 | 3.92 Bn |
| Mar 31, 2025 | 3.56 Bn |
| Dec 31, 2024 | 3.31 Bn |
| Sep 30, 2024 | 3.08 Bn |
| Jun 30, 2024 | 4.20 Bn |
| Mar 31, 2024 | 5.29 Bn |
| Dec 31, 2023 | 5.06 Bn |
| Sep 30, 2023 | 4.84 Bn |
| Jun 30, 2023 | 4.60 Bn |
| Mar 31, 2023 | 4.42 Bn |
| Dec 31, 2022 | 4.30 Bn |
| Sep 30, 2022 | 4.16 Bn |
| Jun 30, 2022 | 3.97 Bn |
| Mar 31, 2022 | 3.82 Bn |
| Dec 31, 2021 | 3.46 Bn |
| Sep 30, 2021 | 3.04 Bn |
| Jun 30, 2021 | 2.83 Bn |
| Mar 31, 2021 | 2.67 Bn |
| Dec 31, 2020 | 2.50 Bn |
| Sep 30, 2020 | 2.37 Bn |
| Jun 30, 2020 | 2.14 Bn |
| Mar 31, 2020 | 2.27 Bn |
| Dec 31, 2019 | 2.51 Bn |
| Sep 30, 2019 | 2.33 Bn |
| Jun 30, 2019 | 2.17 Bn |
| Mar 31, 2019 | 2.01 Bn |
| Dec 31, 2018 | 1.86 Bn |
| Sep 30, 2018 | 1.77 Bn |
| Jun 30, 2018 | 1.68 Bn |
| Mar 31, 2018 | 1.63 Bn |
| Dec 31, 2017 | 1.69 Bn |
| Sep 30, 2017 | 1.39 Bn |
| Jun 30, 2017 | 996.38 Mn |
| Mar 31, 2017 | 692.70 Mn |
| Dec 31, 2016 | 394.73 Mn |
| Sep 30, 2016 | 333.52 Mn |
| Jun 30, 2016 | 262.41 Mn |
| Mar 31, 2016 | 199.45 Mn |
| Dec 31, 2015 | 129.95 Mn |
| Sep 30, 2015 | 71.96 Mn |
| Jun 30, 2015 | 6.88 Mn |
| Mar 31, 2015 | -61.52 Mn |
| Dec 31, 2014 | -85.61 Mn |
| Sep 30, 2014 | -130.29 Mn |
| Jun 30, 2014 | -166.71 Mn |
| Mar 31, 2014 | -177.77 Mn |
| Dec 31, 2013 | -82.16 Mn |
| Sep 30, 2013 | 502,500.00 |
| Jun 30, 2013 | -95.66 Mn |
| Mar 31, 2013 | -169.24 Mn |
| Dec 31, 2012 | -197.45 Mn |
| Sep 30, 2012 | -218.57 Mn |
| Jun 30, 2012 | -233.02 Mn |
| Mar 31, 2012 | -237.97 Mn |
| Dec 31, 2011 | -204.05 Mn |
| Sep 30, 2011 | -158.65 Mn |
| Jun 30, 2011 | -120.13 Mn |
| Mar 31, 2011 | -96.31 Mn |